ISPA-AD

Claire Maussire1, Mohamad El Haj1, Etienne Emmelin2

  • 1Laboratory of Psychology of the Pays de la Loire, LPPL, UR 4638, Nantes University, University of Angers, Nantes, France.

PubMed
まとめ

新しいインタラクティブ社会的問題解決評価(ISPA-AD)を用いて、アルツハイマー病(AD)患者の社会的適応の困難さを調査しました。このツールは、AD患者の社会的問題解決能力の低下を効果的に特定しました。

関連する概念動画

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K